3-10146602-C-T
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP7
The NM_000551.4(VHL):c.429C>T(p.Asp143Asp) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000143 in 1,613,832 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000551.4 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VHL | NM_000551.4 | c.429C>T | p.Asp143Asp | synonymous_variant | Exon 2 of 3 | ENST00000256474.3 | NP_000542.1 | |
VHL | NM_001354723.2 | c.*18-3185C>T | intron_variant | Intron 2 of 2 | NP_001341652.1 | |||
VHL | NM_198156.3 | c.341-3185C>T | intron_variant | Intron 1 of 1 | NP_937799.1 | |||
VHL | NR_176335.1 | n.758C>T | non_coding_transcript_exon_variant | Exon 3 of 4 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152152Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000795 AC: 2AN: 251492Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135918
GnomAD4 exome AF: 0.0000144 AC: 21AN: 1461680Hom.: 0 Cov.: 31 AF XY: 0.0000206 AC XY: 15AN XY: 727150
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152152Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74328
ClinVar
Submissions by phenotype
Von Hippel-Lindau syndrome;C1837915:Chuvash polycythemia Pathogenic:1
This sequence change affects codon 143 of the VHL mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the VHL protein. This variant is present in population databases (rs773556807, gnomAD 0.006%). This variant has been observed in individuals with autosomal recessive erythrocytosis and/or endometrial cancer (PMID: 29891534, 36744932). This variant is also known as D143D. ClinVar contains an entry for this variant (Variation ID: 416990). Studies have shown that this variant alters VHL gene expression (PMID: 29891534; internal data). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant is not likely to affect RNA splicing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -
Von Hippel-Lindau syndrome Uncertain:1
This variant causes a C>T nucleotide change in exon 2 of the VHL gene. An RNA study has reported that this variant results in the incomplete out-of-frame skipping of exon 2 and a corresponding reduction in VHL gene expression in RNA from two homozygous carriers and a compound heterozygous carrier with an intron 2 variant (PMID: 29891534). To our knowledge, this variant has not been reported in individuals affected with VHL-associated hereditary cancer in the literature. This variant has been identified in 2/251492 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:1
The c.429C>T variant (also known as p.D143D), located in coding exon 2 of the VHL gene, results from a C to T substitution at nucleotide position 429. This nucleotide substitution does not change the aspartic acid at codon 143. This variant has been identified in the homozygous state and in trans with a VHL variant in individuals diagnosed with erythrocytosis (Lenglet M et al. Blood, 2018 Aug;132:469-483). This nucleotide position is not well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing; however, RNA studies have detected abnormal splicing associated with this variant (Lenglet M et al. Blood, 2018 Aug;132:469-483, Ambry internal data). Based on the available evidence, the clinical significance of this variant remains unclear. -
Von Hippel-Lindau syndrome;C0031511:Pheochromocytoma;C1837915:Chuvash polycythemia;CN074294:Nonpapillary renal cell carcinoma Uncertain:1
- -
not specified Benign:1
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
not provided Benign:1
VHL: BP4, BP7 -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at